Sanofi Pasteur to use SARS technology to expedite potential COVID-19 vaccine
Sanofi Pasteur revealed today it plans to leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a novel coronavirus (COVID-19) vaccine.
Following in the footsteps of other drugmakers in entering the coronavirus vaccine race, Sanofi Pasteur, the vaccines business of French pharma major Sanofi (Euronext: SAN), will collaborate with the USA’s Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response, expanding the company’s long-standing partnership with the BARDA.
Earlier this month, both Johnson & Johnson’s (NYSE: JNJ) Janssen unit and Regeneron Pharmaceuticals (Nasdaq: REGN) announced collaborations with the BARDA on the development of a novel coronavirus vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze